September 2022

 Sep 29, 2022, 15:45 ET  Overview of Development Pipeline of Melanocortins for Treatment of Ocular Conditions and Role in Resolving Inflammation PL9643 Phase 3 Study Results in Dry Eye Disease Currently Expected 2Q 2023 Palatin Progressing Development Programs in Retinal and Front-of-the-Eye Indications Supported by Breakthrough Science CRANBURY, N.J., Sept. 29, 2022 /PRNewswire/ — Palatin …

Palatin Announces Presentation at the Eyecelerator@AAO 2022 Conference Read More »

 Sep 29, 2022, 13:31 ET  CRANBURY, N.J., Sept. 29, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that the Company will participate in the Ladenburg Thalmann Healthcare Conference on September 29, 2022. Carl Spana, …

Palatin to Participate in Ladenburg Thalmann Healthcare Conference Read More »

 Sep 22, 2022, 07:30 ET  Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Positive Interim Analysis – DMC Recommended Study Sample Size of 350 Patients Topline Results Currently Expected Second Quarter Calendar 2023 Vyleesi® – Gross product sales increased 79%, net product revenue increased 257% and prescriptions dispensed increased 49%, …

Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update Read More »

 Sep 19, 2022, 16:15 ET  CRANBURY, N.J., Sept. 19, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2022 operating results on Thursday, September 22, 2022, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted …

Palatin to Report Fourth Quarter and Fiscal Year End 2022 Results; Teleconference and Webcast to be held on September 22, 2022 Read More »

 Sep 08, 2022, 07:30 ET  Study Designed to Evaluate the Safety, Tolerability, and Efficacy with PL8177 Oral Colon Delivery in Adult Subjects with Active Ulcerative Colitis Oral PL8177 May Provide a Safe and Tolerable Treatment Option for Ulcerative Colitis Patients CRANBURY, N.J., Sept. 8, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical …

Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis Read More »